Antineuronal Nuclear Antibody Type 2 (ANNA-2) Titer, Spinal Fluid
Use
Investigating middle-aged or older patients presenting with unexplained signs of midbrain/cerebellar/brain stem disorders and/or myelopathy. Especially relevant in women with a history of breast cancer or in both genders with a history of tobacco abuse or passive exposure. ANNA-2 serves as a marker for paraneoplastic neurologic autoimmunity, indicating an immune response to neuronal antigens associated with certain cancers, predominately breast, lung, or gynecologic. The test reports an end titer result from cerebrospinal fluid specimens.
Special Instructions
Only orderable as a reflex test. If the indirect immunofluorescence pattern suggests ANNA-2, additional charges may apply.
Limitations
Seronegativity for antineuronal nuclear antibody type 2 (ANNA-2) does not exclude malignancy. ANNA-2 is not detected in serum or spinal fluid of healthy individuals and is found in fewer than 2% of patients with small-cell lung carcinoma without neurologic dysfunction.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
LOINC Codes
- 94357-1
- 94357-1
Result Turnaround Time
5-8 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
1 mL
Container
Sterile vial
Storage Instructions
Refrigerated (preferred): 28 days. Ambient: 72 hours. Frozen: 28 days.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |